Cover Image
Market Research Report

Humanized Mouse & Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO) - Global Forecast to 2022

Published by MarketsandMarkets Product code 424450
Published Content info 191 Pages
Delivery time: 1-2 business days
Price
Back to Top
Humanized Mouse & Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO) - Global Forecast to 2022
Published: March 22, 2018 Content info: 191 Pages
Description

"The humanized mouse models market is projected to grow at a CAGR of 9.9% and humanized rat models market is projected to grow at a CAGR of 8.4%."

The humanized mouse models market is projected to reach USD 128.9 million by 2022 from USD 80.3 million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat models market is expected to reach USD 8.9 million by 2022 from USD 5.9 million in 2017, at a CAGR of 8.4% during the forecast period. The major influencing factors driving the growth of this market are increasing number of research activities involving humanized models, growing demand for personalized medicine, increasing number of R&D activities in pharmaceutical and biotechnology companies, and continuous support in the form of investments and grants from the government and private sectors.

"The cell-based humanized mouse models segment is expected to register the highest growth rate during the forecast period."

On the basis of type, the humanized mouse models are segmented into genetic and cell-based humanized mouse models. The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017-2022). The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.

Furthermore, the cell-based humanized mouse models are categorized into CD34, PBMC, and BLT humanized mouse models. The CD34 humanized mouse models segment is estimated to account for the largest share and register the highest growth rate during the forecast period. The major factors contributing the large share and high growth rate of this segment include usage of CD34 mouse models in in-vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. Thus, the growing application areas of CD34 models are likely to spur the market during the forecast period.

"The Contract Research Organizations (CROs) segment is expected to be the fastest growing end-user segment."

Humanized mouse models market is categorized into three end-user segments, namely, pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The contract research organizations (CROs) segment of the market is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to contract research organizations (CROs).

"In 2017, North America dominated the humanized mouse models market and Asia Pacific is projected to grow at the highest CAGR during the forecast period."

The humanized mouse models market is divided into four major regions- North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the humanized mouse models market. The major factors contributing to the large share of this segment include preclinical activities by CROs and pharmaceutical R&D, increasing monoclonal antibody production, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.

Asia Pacific is expected to register the highest CAGR during the forecast period. The major factors driving the growth of this regional segment include international alliances for R&D activities in China, initiatives to reduce approval time for drugs, growing biomedical and medical research in Japan. Furthermore, the growth of the biomedical industry in India, increase in animal research in Malaysia, and ongoing biomedical research activities in Australia are also driving the growth of the market in Asia Pacific.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1: 31%, Tier 2: 40%, and Tier 3: 29%
  • By Designation - C-level: 37%, Director Level: 40%, Others: 23%
  • By Region - North America: 34%, Europe: 28%, Asia Pacific: 26%, RoW: 12%

The major market players in the humanized mouse models market include: The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Crown Bioscience, Inc. (US), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

Research Coverage:

The report analyzes the market and aims at estimating the market size and the future growth potential of this market based on various segments such as type, application, end user, and region. The report also includes competitive landscape of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on products and services offered by the top players in the global humanized mouse and rat models market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the humanized mouse and rat models market
  • Market Development: Comprehensive information about the lucrative emerging markets by type, application, end user, and region
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global humanized mouse and rat models market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global market
Table of Contents
Product Code: BT 4938

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. HUMANIZED MOUSE MODELS: MARKET OVERVIEW
  • 4.2. HUMANIZED RAT MODELS: MARKET OVERVIEW
  • 4.3. HUMANIZED MOUSE MODELS MARKET SHARE, BY REGION AND END USER (2017)
  • 4.4. HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2017 VS. 2022
  • 4.5. GEOGRAPHIC SNAPSHOT OF THE HUMANIZED MOUSE MODELS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing number of research activities involving humanized models
        • 5.2.1.1.1. Mouse models for immunodeficiency disorders
        • 5.2.1.1.2. Humanized models for cancer
        • 5.2.1.1.3. Mouse models for rare diseases and graft-versus-host disease
      • 5.2.1.2. Growing demand for personalized medicine
      • 5.2.1.3. Continuous support in the form of investments and grants from the government and private sectors
        • 5.2.1.3.1. Funding/grants by the National Institutes of Health (NIH)
        • 5.2.1.3.2. Funding/grants received from other government bodies
      • 5.2.1.4. Increasing number of R&D activities in pharmaceutical and biotechnology companies
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of humanized models
      • 5.2.2.2. Regulations & laws formulated for ethical use of animals
        • 5.2.2.2.1. The Animal Welfare Act (AWA)
        • 5.2.2.2.2. Public Health Service (PHS) policy on humane care and use of laboratory animals
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increased production of monoclonal antibodies
      • 5.2.3.2. Rising demand for humanized rat models
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Advances in zebrafish model development
      • 5.2.4.2. Alternative methods of animal testing
      • 5.2.4.3. Limitations of humanized mouse models

6. CLINICAL TRAILS & RESEARCH STUDIES ASSESSMENT

  • 6.1. INTRODUCTION
  • 6.2. CLINICAL TRIALS
  • 6.3. RESEARCH STUDIES

7. HUMANIZED MOUSE AND RAT MODELS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. HUMANIZED MOUSE MODELS
    • 7.2.1. GENETIC HUMANIZED MOUSE MODELS
    • 7.2.2. CELL-BASED HUMANIZED MOUSE MODELS
      • 7.2.2.1. CD34 humanized mouse models (HU-CD34)
      • 7.2.2.2. PBMC humanized mouse models
      • 7.2.2.3. BLT humanized mouse models
  • 7.3. HUMANIZED RAT MODELS

8. HUMANIZED MOUSE MODELS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. ONCOLOGY
    • 8.2.1. KEY DEVELOPMENTS BY INDUSTRY PLAYERS TO STRENGTHEN CANCER RESEARCH
    • 8.2.2. CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES
  • 8.3. IMMUNOLOGY AND INFECTIOUS DISEASES
    • 8.3.1. GRANTS/FUNDS FOR IMMUNOLOGY AND INFECTIOUS DISEASES RESEARCH
  • 8.4. NEUROSCIENCE
    • 8.4.1. GRANTS/FUNDS FOR NEUROLOGICAL RESEARCH
  • 8.5. TOXICOLOGY
  • 8.6. HEMATOPOIESIS
  • 8.7. OTHER APPLICATIONS
    • 8.7.1. INCREASING FUNDING FOR RARE DISEASES, GRAFT-VS-HOST DISEASES, AND CARDIOVASCULAR DISEASE RESEARCH

9. HUMANIZED MOUSE MODELS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.3. CONTRACT RESEARCH ORGANIZATIONS
  • 9.4. ACADEMIC & RESEARCH INSTITUTIONS

10. HUMANIZED MOUSE MODELS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
      • 10.2.1.1. Availability of support for research in the US
      • 10.2.1.2. Growing focus of oncology research in the US
      • 10.2.1.3. Conferences and other events contributing to the spread of innovation and awareness
      • 10.2.1.4. Growing production of monoclonal antibodies
      • 10.2.1.5. Development of biosimilars boosting the demand for preclinical services
    • 10.2.2. CANADA
      • 10.2.2.1. Growing stem cell research in Canada
      • 10.2.2.2. Government support for the development of protein drugs
  • 10.3. EUROPE
    • 10.3.1. EU5
      • 10.3.1.1. Germany: flourishing biotechnology industry
      • 10.3.1.2. UK: emphasis on quality research results and increase in cell therapy preclinical research
      • 10.3.1.3. France: funding for rare disease projects
      • 10.3.1.4. Italy: growth in the biotechnology and pharmaceutical sector
      • 10.3.1.5. Spain: availability of vc funding for life sciences
    • 10.3.2. REST OF EUROPE (ROE)
      • 10.3.2.1. Growing investments in research by Sweden & Denmark
      • 10.3.2.2. Focus on rare disease research projects
  • 10.4. ASIA PACIFIC
    • 10.4.1. CHINA: STRONG RESEARCH EXPENDITURE, WELL-STRUCTURED CRO INDUSTRY
    • 10.4.2. RISING FOCUS ON PERSONALIZED MEDICINE IN CHINA
    • 10.4.3. INCREASING PUBLIC & PRIVATE INVESTMENTS IN CHINA'S LIFE SCIENCES SECTOR
    • 10.4.4. INITIATIVES TO REDUCE LONG APPROVAL TIMES IN CHINA
    • 10.4.5. JAPAN: GROWTH IN BIOMEDICAL & MEDICAL RESEARCH
    • 10.4.6. RESEARCH INTO REGENERATIVE MEDICINE IN JAPAN
    • 10.4.7. GROWTH OF THE PHARMACEUTICAL INDUSTRY IN INDIA
    • 10.4.8. DEVELOPMENT OF BIOCLUSTERS TO BOOST INDIA'S BIOTECHNOLOGY SECTOR
    • 10.4.9. INFRASTRUCTURAL LIMITATIONS IN INDIA, A KEY HINDRANCE TO MARKET GROWTH
    • 10.4.10. BIOMEDICAL RESEARCH IN AUSTRALIA
    • 10.4.11. GROWTH IN TRANSLATIONAL & BIOMEDICAL RESEARCH IN SINGAPORE
    • 10.4.12. INCREASE IN ANIMAL RESEARCH IN MALAYSIA
    • 10.4.13. RISING PHARMACEUTICAL & BIOTECHNOLOGY R&D ACTIVITIES IN SOUTH KOREA
  • 10.5. REST OF THE WORLD
    • 10.5.1. BRAZIL: GROWTH IN THE PHARMACEUTICAL, BIOTECHNOLOGY, AND RESEARCH INDUSTRIES
    • 10.5.2. FAVORABLE BUSINESS ENVIRONMENT FOR THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES IN SAUDI ARABIA & THE UAE
    • 10.5.3. INCREASING INVESTMENTS IN MEXICO

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
    • 11.2.1. INTRODUCTION
    • 11.2.2. CELL-BASED HUMANIZED MOUSE MODEL MARKET
      • 11.2.2.1. THE JACKSON LABORATORY (US)
      • 11.2.2.2. TACONIC BIOSCIENCES (US)
    • 11.2.3. GENETIC HUMANIZED MOUSE MODEL MARKET
      • 11.2.3.1. HORIZON DISCOVERY GROUP (UK)
      • 11.2.3.2. TACONIC BIOSCIENCES (US)
  • 11.3. COMPETITIVE SCENARIO
    • 11.3.1. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.3.2. GRANTS/FUNDS
    • 11.3.3. PRODUCT LAUNCHES
    • 11.3.4. ACQUISITIONS
    • 11.3.5. EXPANSIONS
    • 11.3.6. OTHER STRATEGIES

12. COMPANY PROFILES (Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*

  • 12.1. THE JACKSON LABORATORY
  • 12.2. TACONIC BIOSCIENCES
  • 12.3. CROWN BIOSCIENCE (SUBSIDIARY OF JSR CORPORATION)
  • 12.4. CHAMPIONS ONCOLOGY
  • 12.5. HORIZON DISCOVERY (SAGE LABS)
  • 12.6. HERA BIOLABS
  • 12.7. GENOWAY
  • 12.8. VITALSTAR BIOTECHNOLOGY
  • 12.9. INGENIOUS TARGETING LABORATORY
  • 12.10. AXENIS
  • 12.11. TRANS GENIC
  • 12.12. HARBOUR ANTIBODIES (A SUBSIDIARY OF HARBOUR BIOMED)
  • 12.13. CHARLES RIVER LABORATORIES

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: SAMPLING FRAME: PRIMARY RESEARCH
  • TABLE 2: INDICATIVE LIST OF CLINICAL TRAILS CONDUCTED ON HUMANIZED MICE MODELS
  • TABLE 3: INDICATIVE LIST OF RESEARCH STUDIES CONDUCTED ON HUMANIZED MICE MODELS
  • TABLE 4: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 5: GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 6: NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 7: EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 8: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 9: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10: NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 11: EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 12: CD34 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 13: NORTH AMERICA: CD34 HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 14: EUROPE: CD34 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15: PBMC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: NORTH AMERICA: PBMC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 17: EUROPE: PBMC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD THOUSAND)
  • TABLE 18: BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD THOUSAND)
  • TABLE 19: NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2015-2022 (USD THOUSAND)
  • TABLE 20: EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD THOUSAND)
  • TABLE 21: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 22: INDICATIVE LIST OF RECENT CANCER RESEARCH STUDIES USING HUMANIZED MOUSE MODELS
  • TABLE 23: HUMANIZED MOUSE MODELS MARKET FOR ONCOLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 24: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR ONCOLOGY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 25: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR ONCOLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 26: HUMANIZED MOUSE MODELS MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 28: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 29: HUMANIZED MOUSE MODELS MARKET FOR NEUROSCIENCE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 30: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR NEUROSCIENCE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 31: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR NEUROSCIENCE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 32: HUMANIZED MOUSE MODELS MARKET FOR TOXICOLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 33: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR TOXICOLOGY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 34: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR TOXICOLOGY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 35: HUMANIZED MOUSE MODELS MARKET FOR HEMATOPOIESIS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 36: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 37: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR HEMATOPOIESIS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 38: HUMANIZED MOUSE MODELS MARKET FOR OTHER APPLICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 39: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 40: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR OTHER APPLICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 41: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 42: HUMANIZED MOUSE MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 43: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 44: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 45: HUMANIZED MOUSE MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 46: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 47: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 48: HUMANIZED MOUSE MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 49: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 50: EUROPE: HUMANIZED MOUSE MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 51: HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 52: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 53: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 54: NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 55: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 56: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 57: NIH FUNDING FOR PROJECTS RELATED TO ANIMAL MODELS
  • TABLE 58: RECENT EVENTS RELATED TO THE ANIMAL MODELS MARKET
  • TABLE 59: US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 60: US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 61: US: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 62: US: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 63: CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 64: CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD THOUSAND)
  • TABLE 65: CANADA: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD THOUSAND)
  • TABLE 66: CANADA: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 67: EUROPE: HUMANIZED MOUSE MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 68: EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 69: EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 70: EUROPE: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 71: EUROPE: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 72: EU5: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 73: EU5: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 74: EU5: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 75: EU5: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 76: ROE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 77: ROE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 78: ROE: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD THOUSAND)
  • TABLE 79: ROE: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 80: JAPAN: SIGNIFICANT PARTNERSHIPS
  • TABLE 81: ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 82: ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD THOUSAND)
  • TABLE 83: ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 84: ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 85: ROW: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 86: ROW: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2015-2022 (USD THOUSAND)
  • TABLE 87: ROW: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION, 2015-2022 (USD THOUSAND)
  • TABLE 88: ROW: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2015-2022 (USD THOUSAND)
  • TABLE 89: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 2015-2018
  • TABLE 90: GRANT/FUND, 2015-2018
  • TABLE 91: PRODUCT LAUNCHES, 2015-2018
  • TABLE 92: ACQUISITIONS, 2015-2018
  • TABLE 93: EXPANSIONS, 2015-2018
  • TABLE 94: OTHER STRATEGIES, 2015-2018

LIST OF FIGURES

  • FIGURE 1: RESEARCH METHODOLOGY: GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET
  • FIGURE 2: RESEARCH DESIGN: GLOBAL HUMANIZED MOUSE AND RAT MODELS MARKET
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: HUMANIZED MOUSE MODELS MARKET, BY APPLICATION (2017)
  • FIGURE 8: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2017 VS. 2022
  • FIGURE 9: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2017 VS. 2022
  • FIGURE 10: HUMANIZED MOUSE MODELS MARKET, BY END USER, 2017 VS. 2022
  • FIGURE 11: HUMANIZED RAT MODELS MARKET OVERVIEW
  • FIGURE 12: THE HUMANIZED MOUSE MODELS MARKET IN ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: INCREASING NUMBER OF RESEARCH ACTIVITIES INVOLVING HUMANIZED MOUSE MODELS, A MAJOR FACTOR DRIVING THE GROWTH OF THE MARKET
  • FIGURE 14: GROWING DEMAND FOR PERSONALIZED MEDICINE, A MAJOR FACTOR DRIVING THE GROWTH OF THE HUMANIZED RAT MODELS MARKET
  • FIGURE 15: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2017
  • FIGURE 16: GENETIC HUMANIZED MOUSE MODELS TO CONTINUE TO DOMINATE THE HUMANIZED MOUSE MODELS MARKET IN 2022
  • FIGURE 17: ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 18: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19: US: CLINICAL TRIALS USING HUMANIZED MICE MODELS, BY INDICATION (2013-2023)
  • FIGURE 20: US: CLINICAL TRIALS USING HUMANIZED MICE MODELS, BY COMPLETION (2013-2023)
  • FIGURE 21: US: CLINICAL TRIALS USING HUMANIZED MICE MODELS, BY PHASE (2013-2023)
  • FIGURE 22: US: RESEARCH STUDIES USING HUMANIZED MICE MODELS, BY INDICATION (2013-2023)
  • FIGURE 23: GENETIC HUMANIZED MOUSE MODELS TO DOMINATE THE MARKET IN 2017
  • FIGURE 24: CD34 HUMANIZED MOUSE MODELS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 25: HUMANIZED RAT MODELS MARKET, 2015-2022 (USD MILLION)
  • FIGURE 26: ONCOLOGY SEGMENT ACCOUNTED FOR LARGEST SHARE OF THE HUMANIZED MOUSE MODELS MARKET IN 2017
  • FIGURE 27: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE HUMANIZED MOUSE MODELS MARKET IN 2017
  • FIGURE 28: NORTH AMERICA WILL CONTINUE TO DOMINATE THE HUMANIZED MOUSE MODELS MARKET IN 2022
  • FIGURE 29: NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET SNAPSHOT
  • FIGURE 30: EUROPE: HUMANIZED MOUSE MODELS MARKET SNAPSHOT
  • FIGURE 31: CELL THERAPY PRECLINICAL STUDIES IN THE UK, 2013-2016
  • FIGURE 32: ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET SNAPSHOT
  • FIGURE 33: ROW: HUMANIZED MOUSE MODELS MARKET SNAPSHOT
  • FIGURE 34: KEY DEVELOPMENTS IN THE HUMANIZED MOUSE MODEL MARKET, 2015-2018
  • FIGURE 35: MARKET SHARE ANALYSIS FOR CELL-BASED HUMANIZED MOUSE MODEL, BY KEY PLAYERS, 2016
  • FIGURE 36: MARKET SHARE ANALYSIS FOR GENETIC HUMANIZED MOUSE MODEL, BY KEY PLAYER, 2016
  • FIGURE 37: THE JACKSON LABORATORY: COMPANY SNAPSHOT (2016)
  • FIGURE 38: CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2016)
  • FIGURE 39: HORIZON DISCOVERY: COMPANY SNAPSHOT (2016)
  • FIGURE 40: GENOWAY: COMPANY SNAPSHOT (2017)
  • FIGURE 41: TRANS GENIC: COMPANY SNAPSHOT (2016)
  • FIGURE 42: CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2016)
Back to Top